A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424

A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)

(2016) T. Powles et al.   ANNALS OF ONCOLOGY

Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience

(2016) Han Hsi Wong et al.   EUROPEAN JOURNAL OF CANCER

The potential of Src inhibitors

(2015) Daniel Elias et al.   Aging-US

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer

(2015) S. M. Reddy et al.   INVESTIGATIONAL NEW DRUGS

The Prognostic Significance of Src and p-Src Expression in Patients with Osteosarcoma

(2015) Yuanlong Xie   MEDICAL SCIENCE MONITOR

SRC: A Century of Science Brought to the Clinic

(2015) Alexey Aleshin et al.   NEOPLASIA

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†

(2014) I. A. McNeish et al.   ANNALS OF ONCOLOGY

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma

(2014) G Peiró et al.   BRITISH JOURNAL OF CANCER

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study

(2014) Sophie Postel-Vinay et al.   EUROPEAN JOURNAL OF CANCER

A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients

(2014) Anna Spreafico et al.   INVESTIGATIONAL NEW DRUGS

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

(2013) John C Araujo et al.   LANCET ONCOLOGY

Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study

(2012) Rosemary A. Hannon et al.   BONE

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma

(2012) Tara C. Gangadhar et al.   INVESTIGATIONAL NEW DRUGS

Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer

(2011) Ayca Gucalp et al.   Clinical Breast Cancer

Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

(2011) A. I. Daud et al.   CLINICAL CANCER RESEARCH

Comprehensive analysis of kinase inhibitor selectivity

(2011) Mindy I Davis et al.   NATURE BIOTECHNOLOGY

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab

(2010) Deric L. Wheeler et al.   CANCER BIOLOGY & THERAPY

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

(2010) R. K. Jain et al.   CLINICAL CANCER RESEARCH

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

(2010) J. Baselga et al.   CLINICAL CANCER RESEARCH

Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies

(2010) E. L. Mayer et al.   CLINICAL CANCER RESEARCH

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

(2009) E. Y. Yu et al.   CLINICAL CANCER RESEARCH

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

(2009) Tim P. Green et al.   Molecular Oncology

The Role of Src in Solid Tumors

(2009) D. L. Wheeler et al.   ONCOLOGIST

Dose Selection in Phase I Studies: Why We Should Always Go for the Most Effective

(2008) Ian E. Haines   JOURNAL OF CLINICAL ONCOLOGY

Dose Selection in Phase I Studies: Why We Should Always Go for the Top

(2008) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY